

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The monoclonal antibody INCA033989 under investigation for the management of myeloproliferative neoplasms inhibits which of the following proteins?**
  - Thrombopoietin receptor
  - MDM2
  - Mutated JAK2
  - Mutated CALR
- 2. In a Phase I study of the BET inhibitor INCB057643 as monotherapy or in combination with ruxolitinib for patients with relapsed/refractory myelofibrosis (MF) or other myeloid neoplasms, what was reported regarding the efficacy endpoints of spleen size reduction and symptom burden improvement?**
  - Spleen size reduction but no symptom burden improvement with the monotherapy and with the combination
  - Spleen size reduction and symptom burden improvement with the combination only
  - Spleen size reduction and symptom burden improvement with the monotherapy and with the combination
- 3. The Phase III ImpactMF study is evaluating imetelstat versus best available therapy in which patients with intermediate-2 or high-risk MF?**
  - Patients with previously untreated disease
  - Patients with relapsed/refractory MF that is JAK inhibitor-naïve
  - Patients with MF that is relapsed/refractory after JAK inhibition
- 4. Which of the following observations was reported with navtemadlin in comparison to best available therapy in the Phase III BOREAS trial for patients with TP53 wild-type MF that was refractory to JAK inhibition?**
  - No improvement in 35% or higher reduction in spleen volume from baseline (SVR35) or in 50% or higher reduction from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (TSS50)
  - Improvement in TSS50 but no improvement in SVR35
  - Improvement in SVR35 and TSS50
- 5. Interim results from an Italian observational study of ruxolitinib dosing and clinical outcomes in patients with MF in a real-world setting demonstrated which finding?**
  - A low minority of patients (<10%) were dosed at a less-than-expected starting dose of ruxolitinib
  - Approximately a third of patients were dosed at a less-than-expected starting dose of ruxolitinib
  - The majority of patients were dosed at a less-than-expected starting dose of ruxolitinib